High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects
Frontiers in Oncology · 16.04.2026 · 16
DOI: 10.3389/fonc.2026.1787786 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 16.04.2026. Verfasst von Lei Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Fuyang Hospital of Traditional Chinese Medicine, Fuyang, China. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adoptive T cell therapy (ACT) is a potent strategy in cancer immunotherapy, but its clinical efficacy is often limited by primary resistance. To overcome this challenge, high-throughput screening technologies have emerged as essential tools for optimizing ACT. By enabling the identification of biologically significant targets and substances from vast libraries, these technologies have accelerated the development of advanced ACT strategies. This review delves into the latest advancements in high-throughput screening, highlighting its applications in genetic screening of T cells and tumor cells, as well as non-genetic screening for small molecules and targeted delivery systems. These insights provide valuable guidance for future research and clinical applications of ACT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Fuyang Hospital of Traditional Chinese Medicine, Fuyang, China.
- Department of General Surgery, Taihe Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Fuyang, China.
- Department of General Surgery, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
- Graduate School, Anhui University of Chinese Medicine, Hefei, China.
Zitieren
APA
Liu, L., Chen, S., Ding, M., Duan, Y., Pu, L., Li, L., Peng, H., & Yu, Q. (2026). High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1787786
Vancouver
Liu L, Chen S, Ding M, Duan Y, Pu L, Li L, et al. High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1787786
BibTeX
@article{Liu2026,
author = {Liu, Lei and Chen, Saisai and Ding, Meng and Duan, Yuqing and Pu, Lingling and Li, Liang and Peng, Hui and Yu, Qingsheng},
title = {High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1787786}
}
EUVIMED